Feasibility and efficacy of 223Ra-dichloride in treatment of bone metastases in patients with castration-refractory prostate cancer (mCRPC)

被引：0
|
作者：
Mazzarri, S. [1 ]
Boni, G. [1 ]
Borso, E. [2 ]
Galli, L. [3 ]
Farnesi, A. [3 ]
Betti, F. [1 ]
Antonacci, L. [1 ]
Traino, A. [4 ]
Ricci, S. [3 ]
Volterrani, D. [1 ]
机构：
[1] Univ Hosp Pisa, Reg Ctr Nucl Med, Pisa, Italy
[2] SantAndrea Hosp La Spezia, Div Nucl Med, La Spezia, Italy
[3] Univ Hosp Pisa, Div Oncol, Pisa, Italy
[4] Univ Hosp, Sect Med Phys, Hlth Phys Unit, Pisa, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP136
引用
收藏
页码：S57 / S58
页数：2
相关论文
共 50 条
  • [21] Efficacy and tolerance of radium-223 dichloride in patients treated for castration-resistant prostate cancer with bone metastases
    Awoudou, C.
    Bathily, E. H. A. L.
    Djigo, M. S.
    Ndong, B.
    Mbodj, M.
    Paulus, P.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2024, 48 (03): : 150 - 157
  • [22] Current possibilities of treatment for visceral metastases in patients with metastatic castration-refractory prostate cancer
    Govorov, A. V.
    Moiseenko, T. N.
    ONKOUROLOGIYA, 2013, 9 (02): : 53 - 56
  • [23] Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
    Hiroji Uemura
    Hirotsugu Uemura
    Nobuaki Matsubara
    Seigo Kinuya
    Makoto Hosono
    Yoko Yajima
    Toshihiko Doi
    International Journal of Clinical Oncology, 2017, 22 : 954 - 963
  • [24] Bone-Seeking Radiopharmaceuticals for Treatment of Osseous Metastases, Part 1: α Therapy with 223Ra-Dichloride
    Pandit-Taskar, Neeta
    Larson, Steven M.
    Carrasquillo, Jorge A.
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (02) : 268 - 274
  • [25] Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases
    Vogelzang, Nicholas J.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (08) : 809 - 819
  • [26] Third-line Therapy for Patients with metastatic castration-refractory Prostate Cancer (mCRPC)
    Rexer, H.
    Hammerer, P.
    Merseburger, A.
    AKTUELLE UROLOGIE, 2019, 50 (02) : 144 - 145
  • [27] Baseline quality of life predicts overall survival in patients with mCRPC treated with 223Ra-dichloride
    Frantellizzi, Viviana
    De Feo, Maria Silvia
    Di Rocco, Arianna
    Pontico, Mariano
    Pani, Arianna
    Farcomeni, Alessio
    Cosma, Laura
    Lazri, Julia
    De Vincentis, Giuseppe
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2020, 23 (01): : 12 - 20
  • [28] Hematotoxicityand non-hematological adverse events of Ra-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases
    Ahmadzadehfar, H.
    Azgomi, K.
    Rogenhofer, S.
    Bundschuh, R.
    Kuerpig, S.
    Thomas, L.
    Essler, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S738 - S739
  • [29] Correlation between Bone Lesion Dosimetry and Pain Outcome in Patients (pts) with Castration-Resistant Prostate Cancer (CRPC) undergoing 223Ra-dichloride Therapy
    Follacchio, G. A.
    Frantellizzi, V.
    Pacilio, M.
    Cassano, B.
    Pani, R.
    Pellegrini, R.
    De Vincentis, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S215 - S215
  • [30] A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases
    Chittenden, Sarah J.
    Hindorf, Cecilia
    Parker, Christopher C.
    Lewington, Valerie J.
    Pratt, Brenda E.
    Johnson, Bernadette
    Flux, Glenn D.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (09) : 1304 - 1309
12345